# Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

> **NCT03144934** · PHASE1 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Human Papillomavirus

## Interventions

- **DRUG:** GX-I7
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03144934
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-16
- **Primary completion:** 2018-03-22
- **Final completion:** 2018-03-22
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03144934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03144934, "Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03144934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*